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Abstract
Background: We previously showed that activation of the bile salt nuclear receptor Farnesoid X Receptor (FXR) protects
against intestinal inflammation in mice. Reciprocally, these inflammatory mediators may decrease FXR activation. We
investigated whether FXR activation is repressed in the ileum and colon of inflammatory bowel disease (IBD) patients in
remission. Additionally, we evaluated whether genetic variation in FXR is associated with IBD.
Methods: mRNA expression of FXR and FXR target gene SHP was determined in ileal and colonic biopsies of patients with
Crohn’s colitis (n = 15) and ulcerative colitis (UC; n = 12), all in clinical remission, and healthy controls (n = 17). Seven
common tagging SNPs and two functional SNPs in FXR were genotyped in 2355 Dutch IBD patients (1162 Crohn’s disease
(CD) and 1193 UC) and in 853 healthy controls.
Results: mRNA expression of SHP in the ileum is reduced in patients with Crohn’s colitis but not in patients with UC
compared to controls. mRNA expression of villus marker Villin was correlated with FXR and SHP in healthy controls, a
correlation that was weaker in UC patients and absent in CD patients. None of the SNPs was associated with IBD, UC or CD,
nor with clinical subgroups of CD.
Conclusions: FXR activation in the ileum is decreased in patients with Crohn’s colitis. This may be secondary to altered
enterohepatic circulation of bile salts or transrepression by inflammatory signals but does not seem to be caused by the
studied SNPs in FXR. Increasing FXR activity by synthetic FXR agonists may have benefit in CD patients.
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Introduction
Inflammatory bowel disease (IBD) may lead to potentially severe
complications and even mortality [1]. Although the exact etiology is
unclear, it is thought to result from a combination of mucosal
immune system dysregulation, hyper-reactivity against the intestinal
microbiota, and a compromised intestinal epithelial barrier function
in genetically predisposed individuals [2]. Genes associated with IBD
highlight key pathogenic mechanisms, including disturbed anti-
bacterial defense (e.g. NOD2, ATG16L1, cathelicidin, defensins) and
barrier function (e.g. PARD3, MAGI2, myosin IXB) [3-8]. In recent
genome-wide association studies, the total number of susceptibility
loci amounts to 99, but this probably accounts for only 16% of the
ulcerative colitis (UC) [9] and 20% of the Crohn’s disease (CD)
heritability [10]. It has been estimated that future genome-wide
association scans will only yield a few more percent of CD and UC
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heritability. Biological pathway-based analyses or studies focusing on
genes involved in established or plausible pathogenetic pathways may
be an alternative approach [11].
The bile salt nuclear Farnesoid X Receptor (NR1H4, nuclear
receptor subfamily 1, group H, member 4, alias FXR on
chromosome 12q23.1) is a member of the superfamily of nuclear
receptors. Nuclear receptors are ligand-activated transcription
factors that, in response to lipophilic ligands (e.g. hormones,
vitamins and dietary lipids), regulate many aspects of mammalian
physiology, including development, reproduction and metabolism
[12,13]. FXR is mainly expressed in the ileum and liver. Upon
activation by bile salts, FXR binds as a heterodimer with Retinoid
X Receptor to the FXR responsive elements on the promoters of
target genes, such as the small heterodimer partner (SHP). Via this
classical route of transactivation, FXR regulates transcription of
genes involved in bile salt synthesis, transport and metabolism in
the liver and intestine [14]. FXR has also been implicated in
immune modulation and barrier function in the intestine [15,16].
We recently reported that pharmacological FXR activation
decreases the severity of inflammation and preserves the intestinal
barrier integrity in two well-established murine colitis models [17].
As already described for other nuclear receptors, the mechanism
by which FXR modulates inflammation is most probably through
transrepression of nuclear transcription factor kappa B (NF-kB)
signaling. Dysregulated activation of NF-kB has previously been
identified as a key factor in the pro-inflammatory response in IBD,
resulting in strongly enhanced expression of pro-inflammatory
genes such as Tumor Necrosis Factor a or Interleukin-1b and
recruitment of an excess of inflammatory cells to the intestinal wall
[18]. Notably, we and others previously showed that there is
reciprocal repression of FXR and NF-kB in vitro and in vivo [19,20].
We therefore investigated FXR and FXR target gene mRNA
expression in patients with CD and UC in clinical remission. In
addition, since FXR acts as a regulator of intestinal inflammation,
we hypothesized that polymorphisms in FXR might be associated
with IBD and tested this hypothesis in a large Dutch cohort of IBD
patients and controls.
Materials and Methods
Patients in mRNA expression study
Seventeen healthy subjects (male/female 7/10; age 55612.1
years), 15 patients with Crohn’s colitis (male/female 5/10; age
4669.8 years) and 12 patients with UC (male/females 4/8; age
4469.8 years) were enrolled in this study. Montreal classification
and medication at the time of endoscopy are shown in Table 1. All
IBD patients were in clinical and endoscopic remission without
significant histological activity. Patients with significant endoscopic
or histological disease activity were excluded. The indication for
colonoscopy was screening for cancer or polyps in healthy controls
and scheduled dysplasia screening in IBD patients. Biopsies were
obtained from the ileum and ascending colon, immediately frozen
in liquid nitrogen and subsequently stored at 280uC, until further
processing. Written informed consent was obtained from all
subjects and the study was approved by the Medical Ethical
Committee of the University Medical Centre Utrecht.
mRNA extraction and qRT-PCR analysis
Human biopsies of ileum and ascending colon were homoge-
nized (Omni TH tissue homogenizer, Omni International,
Kennesaw, USA) and RNA was isolated using RNeasy Micro kit
(Qiagen GmbH, Hilden, Germany) according to the manufactur-
Table 1. Montreal classification and medication of patients of the mRNA expression study.
Characteristic Healthy subjects CD patients UC patients
Number 17 15 12
Male gender (%) 7 (41%) 5 (33%) 4 (33%)
Disease localization (Montreal classification) for CD
L1: ileum 0
L2: colon 8 (53%)
L3: ileocolonic 7 (47%)
L4: upper disease 2 (13%)
Disease behavior (Montreal classification for CD
B1: nonstricturing, nonpenetrating 13 (87%)
B2: stricturing 1 (7%)
B3: penetrating 1 (7%)
P: perianal disease 1 (7%)
Disease localization (Montreal classification) for UC
E1: ulcerative proctitis 0
E2: left-sided (distal) UC 7 (58%)
E3: extensive UC (pancolitis) 5 (42%)
Medication
Steroids 2 (13%) 1 (8%)
Mesalamine 8 (53%) 12 (100%)
Thioguanines 4 (27%) 4 (33%)
Methotrexate 2 (13%) 0
Anti-TNF agents 1 (7%) 0
doi:10.1371/journal.pone.0023745.t001
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er’s instructions. The quantity, quality and integrity of isolated
mRNA were confirmed by absorption measurement and RNA gel
electrophoresis. Subsequently, cDNA was generated from 500 ng
of total RNA using SuperScript II Reverse Transcriptase
(Invitrogen, Carlsbad, CA, USA) and random hexamers (Roche,
Basel, Switzerland). qRT-PCR analysis was carried out using
SYBR green PCR master mix (Biorad, Veenendaal, The Nether-
lands) and a MyIQ real time PCR cycler (Biorad). Values were
quantified using the comparative threshold cycle method. FXR
and its target genes are exclusively expressed in the differentiated
enterocyte on the top of the villi [15,17,19]. In order to estimate
the distribution between villi and crypts in the human biopsies, we
determined mRNA expression of Villin and sucrose isomaltase
(SI), which are both expressed exclusively in differentiated
enterocytes in the villi, and of c-myc and cyclin D1 (CCND1), both
expressed only in the crypts. mRNA expression levels of genes of
interest were normalized to hypoxanthine-guanine phosphoribo-
syltransferase (HPRT), which was shown to be the most stable
reference gene when analyzed with geNorm [21]. Primers are
listed in Table S1.
Patients and controls and the genetic association study
For the genetic association study, a cohort of 2355 Caucasian
IBD patients, consisting of 1162 CD patients and 1193 UC
patients was used. This is a subset of a cohort previously described
by Weersma and colleagues [22]. Patients were recruited from six
University Medical Centers in the Netherlands (details in Table
S2). All patients had a confirmed diagnosis of CD or UC, fulfilling
standard diagnostic criteria according to clinical, endoscopic,
radiological and histopathological findings [23,24], and were
phenotyped according to the Montreal classification [25]. All
patients had given written informed consent and all DNA samples
and data were handled anonymously. The controls consisted of
853 Dutch blood bank donor controls [4]. All control genotypes
were in Hardy-Weinberg equilibrium (data not shown, p.0.05).
SNP selection and genotyping
Nine tagging single nucleotide polymorphisms (SNPs) to cover
the complete FXR gene were selected using Haploview 3.32 [26].
Additionally, two functional SNPs, -1G.T and 518T.C
(rs56163822 and rs61755050), previously described to affect
FXR expression and function [27], respectively, were selected.
Two of the tagging SNP assays failed for technical reasons. With
the remaining seven tagging SNPs, 89% of the FXR gene could be
tagged with a genetic variance above 3%. Rs numbers and
chromosomal location of the SNPs are shown in Table S3.
Genotyping was successful in .98% of all controls, while call rates
for all SNPs in patients were .95%, except for rs11110395 (72%)
and rs10860603 (91%). From one cohort there was less DNA
available so that these SNPs could not be genotyped in that cohort
and rs11110395 failed in some cases for technical reasons.
Genotyping was performed using TaqMan assays on a TaqMan
7900 HT (Applied Biosystems, Foster City, California, USA). All
reported p values are uncorrected unless stated otherwise.
Statistical analysis
Statistical significance in mRNA expression study was deter-
mined by the Student’s t-test or the non-parametric Mann-
Whitney U test as appropriate. Correlation and regression
analyses were used to determine the relationships between
expression values. Statistical significance for correlation was
determined by Spearman’s coefficient test. All statistical calcula-
tions were performed with GraphPad PRISM software (Graphpad
Software, La Jolla, CA, USA). Two-sided p-values ,0.05 are
considered statistically significant.
Statistical analysis of the genetic association study was
performed using 2-tailed x2 tests of case vs. control allele and
haplotype counts for tagging and functional SNPs in Haploview
v4.0. [26]. P-values, odds ratios (OR) and 95% confidence
intervals (95% CI) are shown. The Bonferroni method was used
to correct for multiple testing. All tables show the uncorrected p-
values.
Results
mRNA expression of FXR and its target gene SHP
FXR and its target gene SHP were expressed both in the ileum
and ascending colon of IBD patients in remission and controls.
Expression levels of FXR and SHP were markedly lower in the
right colon compared to the ileum (53% and 55% lower in the
right colon, respectively). There was no significant difference in
ileal FXR expression between controls, CD and UC patients
(Figure 1A). However, ileal expression of SHP was 50% lower in
CD patients compared to controls (p = 0.039), and 33% lower in
UC patients compared to controls (p = 0.21) (Figure 1B). A similar
trend, although not significant, was observed in the colon (data not
Figure 1. FXR target gene expression is decreased in patients
with Crohn’s disease. Scatter plot of mRNA expression of FXR and
SHP in the ileal mucosa of healthy controls (circles), ulcerative colitis
(triangles) and Crohn’s disease patients (squares). Horizontal lines
indicate mean values. *p,0.05 compared to healthy controls.
doi:10.1371/journal.pone.0023745.g001
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shown). FXR and its target genes are exclusively expressed in the
differentiated enterocyte in the villi [15,17,19]. We, therefore, also
correlated FXR and SHP mRNA expression to Villin expression, a
marker exclusively expressed in differentiated enterocytes. Villin
expression was associated with sucrose isomaltase (SI, another gene
expressed in differentiated enterocytes) expression in controls, UC
and CD patients (Figure 2A–C). Villin expression correlated also
with FXR expression in healthy controls. However, the correlation
was lost in UC and CD patients (Figure 2D–F). In addition, Villin
expression showed significant correlation with SHP expression in
healthy controls and UC patients, whereas the correlation was lost
in CD patients (Figure 2G–I). Similar results were found for the
correlation between SI expression and either FXR or SHP (data not
shown). The expression of the crypt markers c-myc and CCND1
were significantly correlated. However, c-myc and CCDN1 did not
correlate to Villin, SI, FXR or SHP expression in any of the groups
(data not shown).
Assessment of FXR genetic variation in IBD patients
A total of 2355 IBD patients and 853 controls were genotyped
with seven tagging SNPs and two functional SNPs in FXR. None
of the functional SNPs was associated with the presence of IBD.
One of the tagging SNPs, however, displayed a significant
association with IBD (rs12313471, p = 0.03, OR 1.32, 95% CI
1.02–1.71; Table S4). CD (n= 1162) and UC patients (n = 1193)
were also separately compared to the 853 healthy controls. The
same tagging SNP (rs12313471) was associated with UC
(p= 0.049, OR 1.32, 95% CI 1.00–1.76; Table S5). None of the
SNPs was associated with CD (Table S6). None of the above
described associations remained significant after Bonferroni
correction for multiple testing.
Subgroup analyses
Phenotypic information on the localization of the disease was
present for 1132 of 1162 (97.4%) patients with CD. We analyzed
whether polymorphisms of FXR were associated with CD location
using the Montreal classification [25]. Patients with L1 (terminal
ileum location; n= 257), L2 (colonic location; n = 295) and L3
(ileocolonic location; n= 580) were compared to CD patients with
other disease locations. Two tagging SNPs displayed a significant
association with ileal CD (L1; rs11110390, p = 0.03, OR 1.26,
95% CI 1.02–1.55 and rs4764980, p= 0.03, OR 0.80, 95% CI
0.65–0.98, Table S7). None of the SNPs was associated with
colonic CD (L2, Table S8). Two SNPs showed a significant
association with ileocolonic CD (L3), namely the functional SNP
518T.C (p=0.015, OR 3.08, 95% CI 1.08–8.83) and one of the
tagging SNPs (rs10860603, p= 0.013, OR 1.39, 95% CI 1.07–
1.81; Table S9). None of these subgroup analyses, however,
remained significant after Bonferroni correction for multiple
testing.
Discussion
Although the exact etiology of IBD is not completely understood,
several lines of evidence point to an impaired intestinal barrier
function and an abnormal immune response in genetically susceptible
Figure 2. FXR and SHP correlate with Villin in healthy controls but not in Crohn’s disease patients. Ileal mRNA expression of SI, FXR and
SHP were related by regression analyses to ileal mRNA expression of differentiation marker Villin in healthy controls (A, D, G), ulcerative colitis (B, E, H)
and Crohn’s disease patients (C, F, I). Spearman’s coefficients and p values are shown. Values in bold show statistically significant correlations;
*p,0.05; **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0023745.g002
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hosts. Recently, we reported that activation of the nuclear receptor
FXR prevents inflammation in animal models of IBD with
improvement of colitis symptoms, preservation of the intestinal
epithelial barrier function and reduction of goblet cell loss [17].
Furthermore, a negative cross-talk between FXR and the inflamma-
tory response at the intestinal level was demonstrated [19], probably
contributing to an attenuated intestinal inflammatory status. In the
present study, we showed that ileal mRNA expression of the FXR
target gene SHP is markedly reduced in Crohn’s colitis patients,
whereas FXR expression remained unchanged. This suggests that
FXR activity is decreased in this IBD subtype. Previously published
genome-wide association scans in IBD patients did not identify loci
containing the FXR gene [9,10]. Since these association studies
explain only a small part of the genetic contribution in IBD, we took a
candidate-gene approach and studied genetic variation in FXR. In the
present study, none of the functional or common tagging SNPs
proved to be significantly associated with CD or UC. Interestingly,
the SNP 518T.C, resulting in the amino acid change M173T,
showed an association with the ileocolonic phenotype of CD
(Montreal L3)(25) (p=0.015, OR 3.08, 95% CI 1.08–8.83). The
same allele has previously been shown to be associated with
intrahepatic cholestasis of pregnancy [27], and to result in a 60%
decrease in transcriptional activity of FXR. Although theM173T was
not significantly associated with CD after correction for multiple
testing, it may well be that it plays a modifier role in the etiology of
CD in conjunction with other genes. In addition, other weak
associations of different tagging SNPs with colonic or ileocolonic
phenotypes disappeared after correction for multiple testing. Thus, a
primary genetic defect underlying the role of FXR in CD could not
be substantiated. Since the functional SNP 518T.C has a very low
prevalence, the possibility of a type II error cannot be excluded.
Moreover, two of the selected tagging SNP assays failed due to
technical reasons. Thus it cannot be excluded that some common
SNPs tagging in the remaining 11% of the FXR gene display an
association with IBD.
Also other explanations accounting for the decreased FXR
activity in CD should be considered. This includes the possibility
that bile salt uptake in the ileum is reduced, for example due to
decreased intestinal transit times. Indeed, several studies have
shown increased fecal excretion of bile salts in patients with CD in
clinical remission [28–31].
Another mechanism contributing to this phenomenon could be
an intrinsically different regulation of bile salt uptake in the ileum
in CD patients [32].
Lastly, reduced FXR target gene expression may be secondary
to the reciprocal inhibition of FXR by NF-kB [19,20]. It is well
established that a range of pro-inflammatory cytokines is
upregulated in the mucosa of IBD patients in remission,
potentially resulting in downregulated FXR activity, leading to
the observed reduced SHP expression in the current study [33].
In conclusion, we found that FXR expression in the ileum is
altered in patients with Crohn’s colitis. This could not be
explained by the presence of common SNPs in the FXR gene.
Treatment with synthetic FXR agonists may overcome the
decrease in FXR activation, possibly resulting in an amelioration
of ileocolitis in patients with CD.
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